Immutep Limited
IMMP
Immutep Limited, a biotechnology company, engages in the research and development of pharmaceutical product candidates. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its lead product candidate is eftilagimod alpha (efti or IMP321), a recombinant protein that is in Phase IIb clinical trial as a chemoimmunotherapy combination for metastatic breaā¦ read more
Healthcare
Biotechnology
13 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$2.95
Price-1.01%
-$0.03
1Y
Price
Market Cap
$434.217m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in AUD.-1924.1%
EBITDA Margin-2059.8%
Net Profit Margin-1768.8%
Free Cash Flow Margin-1924.1%
EBITDA Margin-2059.8%
Net Profit Margin-1768.8%
Free Cash Flow MarginRevenue
$5.044m
+131.3%
1y CAGR+699.5%
3y CAGR+500.8%
5y CAGREarnings
-$61.434m
-143.8%
1y CAGR-58.2%
3y CAGR-45.6%
5y CAGREPS
-$0.42
-116.7%
1y CAGR-39.1%
3y CAGR-23.2%
5y CAGRBook Value
$143.635m
$156.983m
Assets$13.348m
Liabilities$1.625m
DebtDebt to Assets
1.0%
-
Debt to EBITDAFree Cash Flow
-$62.095m
-173.7%
1y CAGR-64.0%
3y CAGR-65.8%
5y CAGRNo items found.
Press Releases
Statements and updates from the company